8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 5, 2026·SEC
REGENXBIO Inc.(RGNX)Earnings, Financials & Key Ratios
RGNX•NASDAQ
Price updated Jun 19, 2026
AboutREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.Show more
- Revenue$170M+104.5%
- EBITDA-$146M+33.0%
- Net Income-$194M+14.6%
- EPS (Diluted)-3.76+18.1%
- Gross Margin88.09%+47.5%
- EBITDA Margin-85.42%+67.2%
- Operating Margin-94.58%+66.2%
- Net Margin-113.75%+58.3%
- ROE-107%-34.6%
RGNX Key Insights
REGENXBIO Inc. (RGNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 2.5x
- ✗Profits declining 11.7% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RGNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RGNX Price & Volume
REGENXBIO Inc. (RGNX) stock price & volume — 10-year historical chart
Loading chart...
RGNX Growth Metrics
REGENXBIO Inc. (RGNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years36.5%
5 Years1.97%
3 Years14.78%
TTM-43.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-83.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-80.06%
Return on Capital
10 Years-26.74%
5 Years-32.43%
3 Years-50.28%
Last Year-46.21%
RGNX Recent Earnings
REGENXBIO Inc. (RGNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$1.72-26.5%
$1.36
Rev
$6M-75.3%
$26M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$1.30-28.7%
$1.01
Rev
$30M-31.0%
$44M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.20+13.0%
$1.38
Rev
$30M-49.8%
$59M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.38-22.1%
$1.13
Rev
$21M-80.6%
$110M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.72vs $1.36-26.5% | $6Mvs $26M-75.3% |
| Q2 2026 | Mar 5, 2026 | $1.30vs $1.01-28.7% | $30Mvs $44M-31.0% |
| Q4 2025 | Nov 6, 2025 | $1.20vs $1.38+13.0% | $30Mvs $59M-49.8% |
| Q3 2025 | Aug 7, 2025 | $1.38vs $1.13-22.1% | $21Mvs $110M-80.6% |
Based on last 12 quarters of dataView full earnings history →
RGNX Peer Comparison
REGENXBIO Inc. (RGNX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare RGNX vs Peers
REGENXBIO Inc. (RGNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RGNX Income Statement
REGENXBIO Inc. (RGNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 10.39M | 218.5M | 35.23M | 154.57M | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M | 87.82M |
Revenue Growth % | 126.48% | 2002.42% | -83.88% | 338.7% | 204.3% | -76.03% | -19.94% | -7.66% | 104.54% | -43.96% |
Cost of Goods Sold | 1.71M | 9.64M | 8.24M | 35.71M | 51.83M | 54.55M | 37.21M | 33.57M | 20.3M | 87.94M |
COGS % of Revenue | 16.44% | 4.41% | 23.39% | 23.11% | 11.02% | 48.39% | 41.24% | 40.28% | 11.91% | - |
Gross Profit | 8.68M▲ 0% | 208.87M▲ 2305.2% | 26.99M▼ 87.1% | 118.85M▲ 340.3% | 418.51M▲ 252.1% | 58.18M▼ 86.1% | 53.03M▼ 8.9% | 49.76M▼ 6.2% | 150.14M▲ 201.7% | -120K▲ 0% |
Gross Margin % | 83.56% | 95.59% | 76.61% | 76.89% | 88.98% | 51.61% | 58.76% | 59.72% | 88.09% | -0.14% |
Gross Profit Growth % | 139.23% | 2305.17% | -87.08% | 340.33% | 252.13% | -86.1% | -8.85% | -6.16% | 201.73% | - |
Operating Expenses | 84.57M | 120.77M | 175.99M | 238.09M | 258.53M | 321.06M | 321.16M | 283.11M | 311.34M | 256.57M |
OpEx % of Revenue | 813.71% | 55.27% | 499.5% | 154.03% | 54.97% | 284.82% | 355.88% | 339.75% | 182.67% | - |
Selling, General & Admin | 27.23M | 36.85M | 51.81M | 63.82M | 79.33M | 85.28M | 88.49M | 76.62M | 82.86M | 83.82M |
SG&A % of Revenue | 261.99% | 16.86% | 147.06% | 41.29% | 16.87% | 75.65% | 98.06% | 91.95% | 48.62% | - |
Research & Development | 57.22M | 83.87M | 124.19M | 166.29M | 181.44M | 242.45M | 232.27M | 208.52M | 228.3M | 228.65M |
R&D % of Revenue | 550.6% | 38.38% | 352.47% | 107.59% | 38.58% | 215.09% | 257.38% | 250.24% | 133.95% | - |
Other Operating Expenses | 116K | 42K | -10K | 7.97M | -2.24M | -6.68M | 397K | -2.03M | 179K | -865K |
Operating Income | -75.89M▲ 0% | 88.1M▲ 216.1% | -149M▼ 269.1% | -119.23M▲ 20.0% | 159.98M▲ 234.2% | -262.88M▼ 264.3% | -268.13M▼ 2.0% | -233.35M▲ 13.0% | -161.2M▲ 30.9% | -256.69M▲ 0% |
Operating Margin % | -730.15% | 40.32% | -422.89% | -77.14% | 34.01% | -233.2% | -297.12% | -280.03% | -94.58% | -292.28% |
Operating Income Growth % | -16.14% | 216.1% | -269.12% | 19.98% | 234.17% | -264.32% | -2% | 12.97% | 30.92% | - |
EBITDA | -73.2M | 92.08M | -141.85M | -110.83M | 169.54M | -249.97M | -250.81M | -217.13M | -145.58M | -245.03M |
EBITDA Margin % | -704.31% | 42.14% | -402.59% | -71.7% | 36.05% | -221.75% | -277.93% | -260.57% | -85.42% | -279% |
EBITDA Growth % | -12.97% | 225.8% | -254.04% | 21.87% | 252.98% | -247.43% | -0.34% | 13.43% | 32.95% | -73.33% |
D&A (Non-Cash Add-back) | 2.69M | 3.98M | 7.15M | 8.41M | 9.56M | 12.91M | 17.32M | 16.21M | 15.62M | 11.66M |
EBIT | -75.89M | 88.1M | -97.49M | -105.24M | 159.98M | -257.15M | -256.78M | -214.44M | -161.2M | -246.88M |
Net Interest Income | 0 | 8.95M | 2.95M | 3.5M | -25.56M | -22.91M | -6.84M | -12.48M | -32.74M | -24.31M |
Interest Income | 0 | 8.95M | 2.95M | 4.27M | 719K | 342K | 25K | 174K | 12.27M | 3.42M |
Interest Expense | 0 | 0 | 0 | 771K | 26.28M | 23.25M | 6.86M | 12.66M | 45.01M | 27.73M |
Other Income/Expense | 2.72M | 16.02M | 51.51M | 13.22M | -18.73M | -17.53M | 4.48M | 6.24M | -32.68M | -33.33M |
Pretax Income | -73.17M▲ 0% | 104.12M▲ 242.3% | -97.49M▼ 193.6% | -106.01M▼ 8.7% | 141.25M▲ 233.2% | -280.4M▼ 298.5% | -263.65M▲ 6.0% | -227.1M▲ 13.9% | -193.88M▲ 14.6% | -290.01M▲ 0% |
Pretax Margin % | -704.02% | 47.65% | -276.7% | -68.59% | 30.03% | -248.75% | -292.15% | -272.54% | -113.75% | -330.23% |
Income Tax | 686K | 4.18M | -2.75M | 5.24M | 13.41M | -84K | -152K | 0 | 0 | 0 |
Effective Tax Rate % | -0.94% | 4.01% | 2.83% | -4.94% | 9.49% | 0.03% | 0.06% | 0% | 0% | 0% |
Net Income | -73.17M▲ 0% | 99.94M▲ 236.6% | -94.73M▼ 194.8% | -111.25M▼ 17.4% | 127.84M▲ 214.9% | -280.32M▼ 319.3% | -263.49M▲ 6.0% | -227.1M▲ 13.8% | -193.88M▲ 14.6% | -290.01M▲ 0% |
Net Margin % | -704.02% | 45.74% | -268.88% | -71.98% | 27.18% | -248.68% | -291.99% | -272.54% | -113.75% | -330.23% |
Net Income Growth % | -16.2% | 236.58% | -194.79% | -17.44% | 214.91% | -319.27% | 6% | 13.81% | 14.63% | -83.91% |
Net Income (Continuing) | -73.17M | 99.94M | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M | -227.1M | -193.88M | -290.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.45▲ 0% | 2.73▲ 211.4% | -2.58▼ 194.5% | -2.98▼ 15.5% | 2.91▲ 197.7% | -6.50▼ 323.4% | -6.02▲ 7.4% | -4.59▲ 23.8% | -3.76▲ 18.1% | -5.53▲ 0% |
EPS Growth % | -2.94% | 211.43% | -194.51% | -15.5% | 197.65% | -323.37% | 7.38% | 23.75% | 18.08% | -80.06% |
EPS (Basic) | -2.45 | 2.73 | -2.58 | -2.98 | 3.01 | -6.50 | -6.02 | -4.59 | -3.76 | - |
Diluted Shares Outstanding | 29.88M | 36.65M | 36.69M | 37.28M | 43.91M | 43.15M | 43.73M | 49.51M | 51.57M | 52.43M |
Basic Shares Outstanding | 29.86M | 36.61M | 36.69M | 37.28M | 42.44M | 43.15M | 43.73M | 49.51M | 51.57M | 52.43M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RGNX Balance Sheet
REGENXBIO Inc. (RGNX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 168M | 337.91M | 345.03M | 531.2M | 518.83M | 415.98M | 334.97M | 278M | 281.28M | 186.52M |
Cash & Short-Term Investments | 160.78M | 319.76M | 296.21M | 475.74M | 457.44M | 364.64M | 275.26M | 234.69M | 230.07M | 150.49M |
Cash Only | 46.66M | 75.56M | 69.51M | 338.43M | 345.21M | 96.95M | 34.52M | 57.53M | 34.47M | 15.23M |
Short-Term Investments | 114.12M | 244.2M | 226.7M | 137.31M | 112.23M | 267.69M | 240.74M | 177.16M | 195.6M | 135.26M |
Accounts Receivable | 473K | 8.59M | 38.15M | 43M | 32.44M | 30.29M | 26.34M | 21.57M | 26.38M | 10.04M |
Days Sales Outstanding | 16.61 | 14.34 | 395.2 | 101.54 | 25.17 | 98.09 | 106.54 | 94.47 | 56.49 | 87.66 |
Inventory | 5.33M | 5.73M | 0 | 10.51M | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 1.14K | 217.11 | - | 107.36 | - | - | - | - | - | - |
Other Current Assets | 1.41M | 3.83M | 4.2M | 1.95M | 10.2M | 7.14M | 18.85M | 12.68M | 24.83M | 25.99M |
Total Non-Current Assets | 30.68M | 205.9M | 152.88M | 176.97M | 595.08M | 417.29M | 239M | 187.99M | 171.75M | 155.38M |
Property, Plant & Equipment | 13.98M | 28.7M | 39.05M | 120.28M | 192.45M | 206.8M | 192.59M | 171.31M | 152.01M | 147.41M |
Fixed Asset Turnover | 0.74x | 7.61x | 0.90x | 1.29x | 2.44x | 0.55x | 0.47x | 0.49x | 1.12x | 0.57x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 15.62M | 150.82M | 103.78M | 46.81M | 391.91M | 200.56M | 38.87M | 10.18M | 15.13M | 88.06M |
Other Non-Current Assets | 1.09M | 26.38M | 10.04M | 9.88M | 10.72M | 9.93M | 7.54M | 6.5M | 4.61M | 7.96M |
Total Assets | 198.68M▲ 0% | 543.81M▲ 173.7% | 497.91M▼ 8.4% | 708.16M▲ 42.2% | 1.11B▲ 57.3% | 833.27M▼ 25.2% | 573.97M▼ 31.1% | 465.99M▼ 18.8% | 453.03M▼ 2.8% | 341.89M▲ 0% |
Asset Turnover | 0.05x | 0.40x | 0.07x | 0.22x | 0.42x | 0.14x | 0.16x | 0.18x | 0.38x | 0.18x |
Asset Growth % | 15.02% | 173.72% | -8.44% | 42.23% | 57.29% | -25.19% | -31.12% | -18.81% | -2.78% | -29.92% |
Total Current Liabilities | 14.44M | 22.18M | 33.68M | 81.45M | 130.47M | 130.43M | 130.27M | 103.19M | 118.09M | 71.11M |
Accounts Payable | 4.83M | 4.41M | 6.41M | 10.62M | 11.39M | 27.21M | 22.79M | 22.8M | 21.36M | 21.21M |
Days Payables Outstanding | 1.03K | 167.05 | 283.86 | 108.56 | 80.19 | 182.1 | 223.49 | 247.9 | 384.06 | 89.74 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47.9M | 7.87M |
Deferred Revenue (Current) | 0 | 600K | 0 | 449K | 3.33M | 1.83M | 148K | 115K | 10.45M | 43.54M |
Other Current Liabilities | 3.82M | 6.95M | 10.9M | 51.59M | 57.74M | 66.67M | 86.04M | 51.92M | 38.39M | 36.12M |
Current Ratio | 11.64x | 15.24x | 10.25x | 6.52x | 3.98x | 3.19x | 2.57x | 2.69x | 2.38x | 2.62x |
Quick Ratio | 11.27x | 14.98x | 10.25x | 6.39x | 3.98x | 3.19x | 2.57x | 2.69x | 2.38x | 2.62x |
Cash Conversion Cycle | 123.83 | 64.4 | - | 100.34 | - | - | - | - | - | -2.08 |
Total Non-Current Liabilities | 1.21M | 12.79M | 14.04M | 248.96M | 219.13M | 186.64M | 131.96M | 103.14M | 232.2M | 249.7M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 147.41M | 63.2M |
Capital Lease Obligations | 0 | 5.85M | 8.87M | 70.15M | 84.93M | 88.8M | 82.22M | 74.13M | 65.22M | 202.29M |
Deferred Tax Liabilities | 0 | 1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.21M | 3.6M | 1.83M | 175.03M | 134.21M | 97.84M | 49.73M | 29.01M | 638K | 186.5M |
Total Liabilities | 15.65M | 34.97M | 47.71M | 330.41M | 349.61M | 317.07M | 262.23M | 206.34M | 350.3M | 320.81M |
Total Debt | 0 | 5.85M | 11.29M | 72.65M | 86.68M | 94.8M | 89.29M | 82.03M | 260.52M | 71.07M |
Net Debt | -46.66M | -69.71M | -58.22M | -265.77M | -258.53M | -2.15M | 54.77M | 24.51M | 226.05M | 55.84M |
Debt / Equity | - | 0.01x | 0.03x | 0.19x | 0.11x | 0.18x | 0.29x | 0.32x | 2.54x | 3.37x |
Debt / EBITDA | - | 0.06x | - | - | 0.51x | - | - | - | - | -0.29x |
Net Debt / EBITDA | - | -0.76x | - | - | -1.52x | - | - | - | - | -0.23x |
Interest Coverage | - | - | - | -136.50x | 6.09x | -11.06x | -37.42x | -16.94x | -3.58x | -8.90x |
Total Equity | 183.03M▲ 0% | 508.85M▲ 178.0% | 450.2M▼ 11.5% | 377.75M▼ 16.1% | 764.3M▲ 102.3% | 516.2M▼ 32.5% | 311.74M▼ 39.6% | 259.65M▼ 16.7% | 102.73M▼ 60.4% | 21.08M▲ 0% |
Equity Growth % | 13.16% | 178.01% | -11.53% | -16.09% | 102.33% | -32.46% | -39.61% | -16.71% | -60.43% | -237.83% |
Book Value per Share | 6.13 | 13.88 | 12.27 | 10.13 | 17.40 | 11.96 | 7.13 | 5.24 | 1.99 | 0.40 |
Total Shareholders' Equity | 183.03M | 508.85M | 450.2M | 377.75M | 764.3M | 516.2M | 311.74M | 259.65M | 102.73M | 21.08M |
Common Stock | 3K | 4K | 4K | 4K | 4K | 4K | 4K | 5K | 5K | 5K |
Retained Earnings | -187.76M | -83.02M | -177.82M | -289.07M | -161.23M | -441.55M | -705.05M | -932.15M | -1.13B | -1.22B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -715K | -720K | 205K | -360K | -2.57M | -15.4M | -4.43M | -741K | -687K | -870K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RGNX Cash Flow Statement
REGENXBIO Inc. (RGNX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -57.99M | 104.65M | -107.7M | -54.06M | 218.88M | -207.49M | -218.41M | -173.13M | -123.96M | -233.78M |
Operating CF Margin % | -557.99% | 47.89% | -305.69% | -34.98% | 46.53% | -184.07% | -242.02% | -207.76% | -72.73% | - |
Operating CF Growth % | -19.43% | 280.45% | -202.92% | 49.81% | 504.87% | -194.8% | -5.26% | 20.73% | 28.4% | -438.35% |
Net Income | -73.17M | 99.94M | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M | -227.1M | -193.88M | -290.01M |
Depreciation & Amortization | 2.69M | 3.98M | 7.15M | 8.41M | 9.56M | 12.91M | 17.32M | 16.21M | 15.62M | 15.52M |
Stock-Based Compensation | 10.61M | 16.64M | 26.85M | 31.95M | 38.81M | 40.79M | 40.27M | 38.46M | 34.56M | 26.03M |
Deferred Taxes | 1.34M | 794K | -38.97M | 3.84M | -1.92M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -347K | -8.93M | -2.68M | -1.23M | 4.36M | 5.16M | -1.61M | -6.23M | 7.96M | 20.82M |
Working Capital Changes | 897K | -7.77M | -5.33M | 14.22M | 40.22M | 13.98M | -10.89M | 5.53M | 11.78M | -6.13M |
Change in Receivables | 561K | -16.8M | -8.62M | -9.9M | 14.12M | 4.82M | 3.94M | 9.71M | -7.66M | 9.02M |
Change in Inventory | -2.2M | 5.35M | 2.37M | 17.85M | 29.3M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 2.62M | -218K | 1.53M | 3.87M | -2.3M | 18.79M | -2.79M | -292K | -2.28M | 1.72M |
Cash from Investing | -4.79M | -279.36M | 93.56M | 122.76M | -406.64M | -11.93M | 190.94M | 103.45M | -15.87M | 9.98M |
Capital Expenditures | -7.16M | -13.28M | -11.72M | -26.87M | -84.17M | -30.72M | -9.96M | -2.44M | -2.41M | -2.63M |
CapEx % of Revenue | 68.89% | 6.08% | 33.26% | 17.38% | 17.9% | 27.26% | 11.04% | 2.92% | 1.42% | 2.99% |
Acquisitions | -479K | -179.71M | -295.98M | -149.63M | -4.99M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 479K | 179.71M | 295.98M | 149.63M | 4.99M | 0 | 0 | 5.78M | 62K | 0 |
Cash from Financing | 84.6M | 204.44M | 8.38M | 200.21M | 195.25M | -28.84M | -34.97M | 92.68M | 116.77M | 108.93M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 82.55M | 190.56M | 1.31M | 1.8M | 218.21M | 1.74M | 6.7M | 132.26M | 1.01M | 1.26M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.19M | 0 | 0 |
Other Financing | 2.05M | 13.88M | 7.06M | 198.41M | -22.96M | -30.58M | -41.67M | -39.58M | 115.76M | 107.66M |
Net Change in Cash | 21.82M▲ 0% | 29.73M▲ 36.3% | -5.77M▼ 119.4% | 268.91M▲ 4760.5% | 7.48M▼ 97.2% | -248.26M▼ 3417.6% | -62.43M▲ 74.9% | 23M▲ 136.8% | -23.06M▼ 200.2% | -114.88M▲ 0% |
Free Cash Flow | -65.15M▲ 0% | 91.37M▲ 240.2% | -119.42M▼ 230.7% | -80.93M▲ 32.2% | 134.7M▲ 266.4% | -238.21M▼ 276.8% | -228.37M▲ 4.1% | -175.56M▲ 23.1% | -126.38M▲ 28.0% | -236.4M▲ 0% |
FCF Margin % | -626.88% | 41.82% | -338.96% | -52.36% | 28.64% | -211.32% | -253.06% | -210.69% | -74.15% | -269.18% |
FCF Growth % | -14.89% | 240.24% | -230.7% | 32.23% | 266.44% | -276.85% | 4.13% | 23.12% | 28.02% | -171.9% |
FCF per Share | -2.18 | 2.49 | -3.25 | -2.17 | 3.07 | -5.52 | -5.22 | -3.55 | -2.45 | -4.51 |
FCF Conversion (FCF/Net Income) | 0.79x | 1.05x | 1.14x | 0.49x | 1.71x | 0.74x | 0.83x | 0.76x | 0.64x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 21.64M | 23.12M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 3.44M | 904K | 0 | 6M | 11.81M | 0 | 0 | 0 | 0 |
RGNX Key Ratios
REGENXBIO Inc. (RGNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -42.45% | 28.89% | -19.76% | -26.87% | 22.39% | -43.78% | -63.65% | -79.49% | -107% | -232.5% |
Return on Invested Capital (ROIC) | -41.65% | 22.96% | -26.89% | -35.49% | 38.85% | -38.67% | -45.67% | -53.79% | -39.45% | -77.92% |
Gross Margin | 83.56% | 95.59% | 76.61% | 76.89% | 88.98% | 51.61% | 58.76% | 59.72% | 88.09% | -0.14% |
Net Margin | -704.02% | 45.74% | -268.88% | -71.98% | 27.18% | -248.68% | -291.99% | -272.54% | -113.75% | -330.23% |
Debt / Equity | - | 0.01x | 0.03x | 0.19x | 0.11x | 0.18x | 0.29x | 0.32x | 2.54x | 3.37x |
Interest Coverage | - | - | - | -136.50x | 6.09x | -11.06x | -37.42x | -16.94x | -3.58x | -8.90x |
FCF Conversion | 0.79x | 1.05x | 1.14x | 0.49x | 1.71x | 0.74x | 0.83x | 0.76x | 0.64x | 0.82x |
Revenue Growth | 126.48% | 2002.42% | -83.88% | 338.7% | 204.3% | -76.03% | -19.94% | -7.66% | 104.54% | -43.96% |
Related:RGNX Dividend History·RGNX Revenue History·RGNX Price History·RGNX P/E History·RGNX Financial Ratios·RGNX Institutional Holders
RGNX SEC Filings & Documents
REGENXBIO Inc. (RGNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
RGNX Frequently Asked Questions
REGENXBIO Inc. (RGNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
REGENXBIO Inc. (RGNX) reported $87.8M in revenue for fiscal year 2025. This represents a 1343% increase from $6.1M in 2013.
REGENXBIO Inc. (RGNX) grew revenue by 104.5% over the past year. This is strong growth.
REGENXBIO Inc. (RGNX) reported a net loss of $290.0M for fiscal year 2025.
Dividend & Returns
REGENXBIO Inc. (RGNX) has a return on equity (ROE) of -107.0%. Negative ROE indicates the company is unprofitable.
REGENXBIO Inc. (RGNX) had negative free cash flow of $236.4M in fiscal year 2025, likely due to heavy capital investments.